News | May 24, 2011

Cordis Launches Two New Products at EuroPCR Congress

May 24, 2011 - Cordis announced it has obtained CE mark for its Empira and Empira NC RX percutaneous transluminal coronary angioplasty (PTCA) dilatation catheters for the treatment of coronary artery disease. The Empira systems are designed to enable interventional cardiologists to open patients' narrowed coronary arteries during angioplasty and stenting procedures. The company also highlighted its radial access products at EuroPCR 2011.

The Empira family of PTCA dilatation catheters incorporates several design and technology changes that have the potential to improve crossability and recrossability, allowing a physician to reach even hard-to-treat lesions. Both catheters utilize the next generation Dralyn Flex balloon material, which is 50 percent more flexible than the Duralyn balloon material used in the current dilatation catheters. Empira will be made available in selected sizes to a limited number of centers in Europe during the summer. A full European commercial launch of Empira is planned for Q4 2011.

Cordis also announced the launch in Europe of Radial Solutions, a portfolio for transradial interventions. New to the portfolio is the Cordis RadialSource Transradial Access Kit. RadialSource transradial sheaths are designed to provide cardiologists with atraumatic and smooth access to the radial artery during diagnostic and interventional procedures.

The RadialSource transradial sheath incorporates a new tapering design in conjunction with a lubricious coating, offering the benefits of low insertion force with a smooth atraumatic entry, while enabling stability during procedure and ease of removal. Physicians will be offered a choice of kit with a bare metal or a polymer-coated guide wire.

Cordis Radial Solutions encompass Cordis' well known guiding and diagnostic catheters with new specific radial shapes, transradial sheath introducer, guide wires and professional education training.

"Radial access, with much fewer bleeding complications, is becoming the dominant access site in many countries," said Douglas G. Fraser, MB, BChir, MRCP, DM, interventional cardiologist, Manchester Heart Centre, Manchester Royal Infirmary, U.K.

Related Content

Cardiovascular Systems Expands Product Portfolio for Peripheral and Coronary Interventions
News | Balloon Catheter | January 24, 2018
Cardiovascular Systems Inc. recently announced two new partnerships broadening the company’s product portfolio. CSI is...
Abbott recalls its NC Balloon catheters
News | Balloon Catheter | May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Videos | Balloon Catheter | November 16, 2016
A discussion with Todd Brinton, M.D., about the newly FDA-cleared Shockwave Medical Lithoplasty System, at the Transc
NuCryo Vascular, Next Generation Cryoplasty Inflation Device, PolarCath Balloon Dilatation System

PolarCath Balloon Dilatation System image courtesy of NuCryo Vascular

Technology | Balloon Catheter | March 28, 2016
NuCryo Vascular LLC announced the launch of the Next Generation Cryoplasty Inflation device. The device received U.S....
NuCryo Vascular, FDA clearance, next-gen, PolarCath System, cryoplasty inflation device
Technology | Balloon Catheter | January 12, 2016
NuCryo Vascular LLC announced that they have received U.S. Food and Drug Administration (FDA) 510(k) clearance on the...
Videos | Balloon Catheter | October 30, 2015
Todd Brinton, M.D., clinical associate professor and consulting associate professor of bioengineering at Stanford Uni
Overlay Init